Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate
- 1 August 2003
- journal article
- clinical trial
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 11 (8), 539-547
- https://doi.org/10.1007/s00520-003-0477-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001
- Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.2000
- Effect of First Treatment with Aminobisphosphonates Pamidronate and Ibandronate on Circulating Lymphocyte SubpopulationsJournal of Bone and Mineral Research, 2000
- Comparative Tolerability of Drug Therapies for Hypercalcaemia of MalignancyDrug Safety, 1999
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.Journal of Clinical Endocrinology & Metabolism, 1994
- Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosagesAmerican Journal Of Medicine, 1993
- Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer.1993
- Cancer-Associated Hypercalcemia: Morbidity and MortalityAnnals of Internal Medicine, 1990
- RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATESThe Lancet, 1983